ALPS【ALPS】銘柄情報

ALPS Group Inc (ALPS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.571

( -1.55% )

買値

0.571

売値

0.588

出来高

3,455,156

0.581 日の範囲 0.60

0.1425 52 週間の範囲 1.75

時価総額

95.015M

前日終値

0.58

始値

0.5897

時刻

253

0.571

(formt)

最終取引時間

財務取引量

US$ 2,047,751

VWAP

0.592665

平均取引量 (3 か月)

US$ 31,013

発行済株式数

166,400,326

配当利回り

PER

-13.32

1 株当たり利益 (EPS)

-0.05

歳入

3.74M

純利益

-2.64M

Alps Group Inc, a biotechnology company, provides research and development, medical services, and wellness solutions for advanced therapies. The company is based in Kuala Lumpur, Malaysia. Alps Group Inc, a biotechnology company, provides research and development, medical services, and wellness solutions for advanced therapies. The company is based in Kuala Lumpur, Malaysia.

セクター

業界

ウェブサイト

alps-holdings.com

本社

Kuala Lumpur, Malaysia

設立

ALPS Group Inc is listed in the sector of the ナスダック市場 with ticker ALPS. The last closing price for ALPS was US$0.58. Over the last year, ALPS shares have traded in a share price range of US$ 0.1425 to US$ 1.75.

ALPS currently has 166,400,326 shares in issue. The market capitalisation of ALPS is US$95.01 million. ALPS has a price to earnings ratio (PE ratio) of -13.32.

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq:...

Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022

KUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq:...

Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the...

Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight

KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”...

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the...

Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the...

SPAC News From The Last Seven Days

The Last Week’s Deals Cantor Equity Partners II, Inc. (NASDAQ:CEPT) has announced it is to acquire Securitize, a platform for tokenizing...

Alps Announces Closing of Business Combination with Globalink Investment Inc.

KUALA LUMPUR, Malaysia and NEWARK, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.079	-12.1538461538	0.65	0.86	0.5635	124910	0.63592391	CS
4	-0.1611	-22.0051905477	0.7321	0.86	0.5635	58693	0.66795431	CS
12	-0.401501	-41.2854074186	0.972501	1.02	0.5635	33245	0.73545683	CS
26	-0.3553	-38.3569038109	0.9263	1.39	0.5635	38899	0.90085273	CS
52	0.4285	300.701754386	0.1425	1.75	0.1425	104336	1.03927448	CS
156	-0.039	-6.39344262295	0.61	1.75	0.14	57491	0.73197647	CS
260	-4.429	-88.58	5	6.18	0.14	72231	0.88457199	CS